ImmunityBio, Inc.
For the period ended Dec 31, 2025. Filed Feb 23, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Feb 23, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Signatures
Pursuant to the requirements of Section 13 or 15(d) of the Securities Act of 1934, as amended, the registrant has duly caused this Annual Report to be signed on its behalf by the undersigned, thereunto duly authorized.
| IMMUNITYBIO, INC. | ||
| Registrant | ||
| Date: February 23, 2026 | By: | /s/ Richard Adcock |
|---|---|---|
| Richard Adcock | ||
| Chief Executive Officer | ||
| (Principal Executive Officer) | ||
| Date: February 23, 2026 | By: | /s/ David C. Sachs |
| David C. Sachs | ||
| Chief Financial Officer | ||
| (Principal Financial Officer) | ||
| Date: February 23, 2026 | By: | /s/ Regan J. Lauer |
| Regan J. Lauer | ||
| Chief Accounting Officer | ||
| (Principal Accounting Officer) | ||
POWER OF ATTORNEY
Each person whose signature appears below constitutes and appoints Richard Adcock, David C. Sachs and Philip LoScalzo, and each of them, as his or her true and lawful attorney-in-fact and agent, with full power of substitution and resubstitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign any and all amendments to this Annual Report, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or any of them, or their or his substitutes, may lawfully do or cause to be done by virtue thereof.
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, this Annual Report has been signed below by the following persons on behalf of the registrant in the capacities and on the dates indicated.
| Signature | Title | Date |
|---|---|---|
| /s/ Patrick Soon-Shiong | Global Chief Scientific and Medical Officer, and Executive Chairman of the Board of Directors | February 23, 2026 |
| Patrick Soon-Shiong | ||
| /s/ Richard Adcock | Chief Executive Officer, President and Director(Principal Executive Officer) | February 23, 2026 |
| Richard Adcock | ||
| /s/ David C. Sachs | Chief Financial Officer(Principal Financial Officer) | February 23, 2026 |
| David C. Sachs | ||
| /s/ Regan J. Lauer | Chief Accounting Officer(Principal Accounting Officer) | February 23, 2026 |
| Regan J. Lauer | ||
| /s/ Barry J. Simon | Chief Corporate Affairs Officer and Director | February 23, 2026 |
| Barry J. Simon | ||
| /s/ Michael Blaszyk | Director | February 23, 2026 |
| Michael D. Blaszyk | ||
| /s/ Wesley Clark | Director | February 23, 2026 |
| Wesley Clark | ||
| /s/ Cheryl L. Cohen | Lead Independent Director | February 23, 2026 |
| Cheryl L. Cohen | ||
| /s/ Linda Maxwell | Director | February 23, 2026 |
| Linda Maxwell | ||
| /s/ Christobel Selecky | Director | February 23, 2026 |
| Christobel Selecky | ||
| /s/ Bruce Wendel | Director | February 23, 2026 |
| Bruce Wendel | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.